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Analysis of research and development (R&D) productivity of the 
pharmaceutical industry has increased. A pharmaceutical company needs to 
improve R&D productivity to sustain earnings and some papers argue the 
decline of R&D productivity is a cause of mergers and acquisitions (M&A). A 
conventional method for measuring R&D productivity on an individual 
company basis is based on R&D efficiency, i.e., a ratio of R&D spending to 
number of successful new molecular entities (NMEs), and there are 
limitations to examining relationships between R&D productivity and 
industry consolidation. Few methods incorporate the nature of the 
pharmaceutical industry, including differences in therapeutic category risk 
profiles, and measure R&D productivity on an individual company basis. The 
goal of this dissertation is to develop a novel method to measure R&D 
productivity of an individual pharmaceutical company incorporating 
industry characteristics. Based on these outcomes, relationships between 
R&D productivity and industry consolidation and between R&D productivity 
and therapeutic categories are investigated.  
Out of 24 publicly listed Japanese companies since 1980, 15 are selected 
using one input variable (actual R&D spending) and three output variables 
(accumulated number of weighted NMEs, sales, and operating profit). The 
weight is assigned based on development stage using an interview form 
regarding R&D spending: 50% for in-licensed NME and 20% for 
co-development NME. Annual reports from 1970 to 1997 are used for 
financial information and 1997 is the endpoint because it marks the end of 
the non-M&A period. 
Out of 50 global pharmaceutical companies including seven Japanese 
pharmaceutical companies, 21 are selected and three variables are 
employed: R&D spending, number of NMEs, and aggregated net present 
value (NPV). R&D spending is obtained from annual reports from 2002 to 
2012. We include 604 NMEs in the data set that were engaged in a Phase III 
study initiated between 2002 and 2007 or between 2008 and 2012 (using 
annual reports). NPVs of 21 global pharmaceutical companies from 
Pharmapipeline® were obtained from Barclays Capital. The data collection 
endpoint is 2007 because it marks a period just before several large M&A 
transactions. 
To visualize company R&D productivity among industry peers, a relative 
ranking approach is used to eliminate an impact on size effect. This approach 
is based on data envelopment analysis (DEA) since DEA is based on distance 
from the efficiency frontier constructed from optimal companies. The 
Malmquist index is employed to identify historical R&D productivity 
changes in Japanese companies from 1980 to 1997. 
We deconstruct R&D productivity into two components: cost efficiency 
(number of NMEs divided by R&D spending) and product value effectiveness 
(product value divided by number of NMEs). Based on these scores, a 
benchmark is constructed that employs two-stage DEA. An advantage of 
using two-stage DEA is the ability to measure overall R&D productivity. The 
cost efficiency index (number of optimized NMEs divided by R&D spending) 
and product value effectiveness index (product value divided by number of 
optimized NMEs) for each company are measured. The optimized number of 
NMEs minimizes the difference between two indices to estimate overall 
optimal R&D productivity. A R&D productivity map (RDP map) is 
constructed using the cost efficiency index (x-axis of the map) and product 
value effectiveness (y-axis). 
Results using the Malmquist index indicate that the R&D productivity of the 
15 Japanese companies declined and that there is dispersion of R&D 
productivity deterioration. RDP map results illustrate that companies with 
optimal cost efficiency (p <0.05) merged with companies with the 
least-optimal product value effectiveness (p <0.10). The four largest 
therapeutic franchises have optimal product value effectiveness (p <0.01), 
companies involved in antibiotics have optimal cost efficiency (p <0.1), and 
companies involved in lifestyle diseases have the least-optimal cost efficiency 
(p <0.001). Selection of a particular franchise may lead to deterioration of 
R&D productivity in the future. 
Results indicate that out of 21 companies in 2007, 11 had optimal cost 
efficiency, two had optimal product value effectiveness, and one company had 
both. Companies with lower cost efficiency scores were more likely to actively 
engage in M&A (p<0.05) in 2007. Results indicate that in 2012, one company 
had optimal cost efficiency, two had optimal product value effectiveness, and 
no company had both. This dissertation also illustrates the cause of M&A 
among pharmaceutical companies, which was not explained by previous 
literature. 
Statistical results indicate companies involved in vaccines were less cost 
efficient (p <0.001) and those involved in the central nervous system (CNS) 
had the least product value effectiveness (p <0.001). In 2012, companies that 
developed cancer and respiratory therapies (p <0.001) were less cost efficient. 
Franchise selection criteria may vary among companies but the criteria 
impacts future R&D productivity. 
Based on these results, at least two suggestions to the pharmaceutical 
industry can be presented. First, to sustain R&D productivity over the long 
term, companies should focus on dominant therapeutic franchises and 
balance cost efficiency with product value effectiveness. Second, if a company 
becomes least optimal or fails significantly to catch up with the benchmark, 
pursuing M&A may no longer solve the decline of R&D productivity. As 
companies seek economies of scale and become successful, R&D spending 
increases and the sustainability issue arises. Companies have at least three 
options: 1) devote to potentially high-value products with high failure risk, 2) 
diversify therapeutic categories, and 3) collaboration.  
The R&D productivity model and map measure an individual company’s 
R&D productivity with two dimensions to visualize relative status in the 
pharmaceutical industry, and to indicate a possible solution to improve R&D 
productivity. While there are several useful R&D management tools, the 
RDP map provides another way to inspect current R&D strategy. The map 
shows how to improve productivity by either complementing cost efficiency 
or product value effectiveness, or both.  
